Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 129, Issue 16

April 20 2017

In this Issue

INSIDE BLOOD COMMENTARIES
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
LETTERS TO BLOOD
BLOOD WORK
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY

Efficacy in the margins of NHL with ibrutinib
Clinical Trials & Observations

Paul M. Barr

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

INSIDE BLOOD COMMENTARY

Multiple myeloma cells sent “PAKing”!

Paola Neri,Nizar J. Bahlis

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

INSIDE BLOOD COMMENTARY

Anti-CD20-IL-21 fusokine: the tail wags the dog

Stephen M. Ansell

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

INSIDE BLOOD COMMENTARY

I am SAMD9L: 7q regulator I am

Matthew Collin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

INSIDE BLOOD COMMENTARY

Making thrombolysis safer in stroke

David Gailani

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

INSIDE BLOOD COMMENTARY

Complement and clot

Vahid Afshar-Kharghan

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

REVIEW ARTICLE

Mouse models of MLL leukemia: recapitulating the human disease

Thomas A. Milne

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

CLINICAL TRIALS AND OBSERVATIONS

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Clinical Trials & Observations

Ariela Noy,Sven de Vos,Catherine Thieblemont,Peter Martin,Christopher R. Flowers,Franck Morschhauser,Graham P. Collins,Shuo Ma,Morton Coleman,Shachar Peles,Stephen Smith,Jacqueline C. Barrientos,Alina Smith,Brian Munneke,Isaiah Dimery,Darrin M. Beaupre,Robert Chen

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

LYMPHOID NEOPLASIA

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Mariateresa Fulciniti,Joaquin Martinez-Lopez,William Senapedis,Stefania Oliva,Rajya Lakshmi Bandi,Nicola Amodio,Yan Xu,Raphael Szalat,Annamaria Gulla,Mehmet K. Samur,Aldo Roccaro,Maria Linares,Michele Cea,Erkan Baloglu,Christian Argueta,Yosef Landesman,Sharon Shacham,Siyuan Liu,Monica Schenone,Shiaw-Lin Wu,Barry Karger,Rao Prabhala,Kenneth C. Anderson,Nikhil C. Munshi

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity

Shruti Bhatt,Salma Parvin,Yu Zhang,Hyun-Mi Cho,Kranthi Kunkalla,Francisco Vega,John M. Timmerman,Seung-Uon Shin,Joseph D. Rosenblatt,Izidore S. Lossos

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines
CME

Frederika A. van Nimwegen,Georgios Ntentas,Sarah C. Darby,Michael Schaapveld,Michael Hauptmann,Pieternella J. Lugtenburg,Cecile P. M. Janus,Laurien Daniels,Flora E. van Leeuwen,David J. Cutter,Berthe M. P. Aleman

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

MYELOID NEOPLASIA

Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms

Bianca Tesi,Josef Davidsson,Matthias Voss,Elisa Rahikkala,Tim D. Holmes,Samuel C. C. Chiang,Jonna Komulainen-Ebrahim,Sorina Gorcenco,Alexandra Rundberg Nilsson,Tim Ripperger,Hannaleena Kokkonen,David Bryder,Thoas Fioretos,Jan-Inge Henter,Merja Möttönen,Riitta Niinimäki,Lars Nilsson,Cornelis Jan Pronk,Andreas Puschmann,Hong Qian,Johanna Uusimaa,Jukka Moilanen,Ulf Tedgård,Jörg Cammenga,Yenan T. Bryceson

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

THROMBOSIS AND HEMOSTASIS

Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke

Fabrício Simão,Tuna Ustunkaya,Allen C. Clermont,Edward P. Feener

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development

Saravanan Subramaniam,Kerstin Jurk,Lukas Hobohm,Sven Jäckel,Mona Saffarzadeh,Kathrin Schwierczek,Philip Wenzel,Florian Langer,Christoph Reinhardt,Wolfram Ruf

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations
Brief Report

Alessio Branchini,Mattia Ferrarese,Matteo Campioni,Giancarlo Castaman,Rosella Mari,Francesco Bernardi,Mirko Pinotti

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

TRANSPLANTATION

Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study
Clinical Trials & Observations

Parinda A. Mehta,Stella M. Davies,Thomas Leemhuis,Kasiani Myers,Nancy A. Kernan,Susan E. Prockop,Andromachi Scaradavou,Richard J. O’Reilly,David A. Williams,Leslie Lehmann,Eva Guinan,David Margolis,K. Scott Baker,Adam Lane,Farid Boulad

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality

Joshua A. Hill,Bryan T. Mayer,Hu Xie,Wendy M. Leisenring,Meei-Li Huang,Terry Stevens-Ayers,Filippo Milano,Colleen Delaney,Mohamed L. Sorror,Brenda M. Sandmaier,Garrett Nichols,Danielle M. Zerr,Keith R. Jerome,Joshua T. Schiffer,Michael Boeckh

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

LETTERS TO BLOOD

Published abstracts at international meetings often over- or underestimate the initial response rate
Clinical Trials & Observations

Ofrat Beyar-Katz,Jacob M. Rowe,Lauren E. Townsend,Martin S. Tallman,Rivka Hadomi,Netanel A. Horowitz

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial
Clinical Trials & Observations

Pier Luigi Zinzani,Cinzia Pellegrini,Annalisa Chiappella,Alice Di Rocco,Flavia Salvi,Maria Giuseppina Cabras,Lisa Argnani,Vittorio Stefoni

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia

Colin D. Godwin,George B. McDonald,Roland B. Walter

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

BLOOD WORK

MDS with isolated del(5q) and internuclear bridging

Zhaodong Xu,Jean McGowan-Jordan

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Risk of heart failure following Hodgkin lymphoma
CME

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Cover Image
Front Matter
Table of Contents
Back Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Close Modal

Latest
Most Read
Most Cited

The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy

RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT

Type 1 von Willebrand disease: does it need a sibling?

Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022;140(7):756-768.

Qualitative low VWF

Advertisement intended for health care professionals

Table of Contents

INSIDE BLOOD COMMENTARIES

Efficacy in the margins of NHL with ibrutinib
Clinical Trials & Observations

Multiple myeloma cells sent “PAKing”!

Anti-CD20-IL-21 fusokine: the tail wags the dog

I am SAMD9L: 7q regulator I am

Making thrombolysis safer in stroke

Complement and clot

REVIEW ARTICLE

Mouse models of MLL leukemia: recapitulating the human disease

CLINICAL TRIALS AND OBSERVATIONS

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Clinical Trials & Observations

LYMPHOID NEOPLASIA

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines
CME

MYELOID NEOPLASIA

Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms

THROMBOSIS AND HEMOSTASIS

Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development

Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations
Brief Report

TRANSPLANTATION

Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study
Clinical Trials & Observations

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality

LETTERS TO BLOOD

Published abstracts at international meetings often over- or underestimate the initial response rate
Clinical Trials & Observations

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial
Clinical Trials & Observations

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia

BLOOD WORK

MDS with isolated del(5q) and internuclear bridging

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Risk of heart failure following Hodgkin lymphoma
CME

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

INSIDE BLOOD COMMENTARIES

Efficacy in the margins of NHL with ibrutinib Free Clinical Trials & Observations

Multiple myeloma cells sent “PAKing”! Free

Anti-CD20-IL-21 fusokine: the tail wags the dog Free

I am SAMD9L: 7q regulator I am Free

Making thrombolysis safer in stroke Free

Complement and clot Free

REVIEW ARTICLE

Mouse models of MLL leukemia: recapitulating the human disease Free

CLINICAL TRIALS AND OBSERVATIONS

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma Free Clinical Trials & Observations

LYMPHOID NEOPLASIA

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma Free

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity Free

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines Free CME

MYELOID NEOPLASIA

Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms Free

THROMBOSIS AND HEMOSTASIS

Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke Free

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development Free

Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations Free Brief Report

TRANSPLANTATION

Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study Free Clinical Trials & Observations

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality Free

LETTERS TO BLOOD

Published abstracts at international meetings often over- or underestimate the initial response rate Free Clinical Trials & Observations

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial Free Clinical Trials & Observations

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia Free

BLOOD WORK

MDS with isolated del(5q) and internuclear bridging Free

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Risk of heart failure following Hodgkin lymphoma Free CME

Email alerts

ASH Publications

American Society of Hematology

Efficacy in the margins of NHL with ibrutinib
Clinical Trials & Observations

Multiple myeloma cells sent “PAKing”!

Anti-CD20-IL-21 fusokine: the tail wags the dog

I am SAMD9L: 7q regulator I am

Making thrombolysis safer in stroke

Complement and clot

Mouse models of MLL leukemia: recapitulating the human disease

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Clinical Trials & Observations

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines
CME

Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms

Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development

Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations
Brief Report

Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study
Clinical Trials & Observations

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality

Published abstracts at international meetings often over- or underestimate the initial response rate
Clinical Trials & Observations

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial
Clinical Trials & Observations

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia

MDS with isolated del(5q) and internuclear bridging

Risk of heart failure following Hodgkin lymphoma
CME